Cancer Treatment News and Research

RSS

Aflac raises $1.16 million through a grant campaign for pediatric cancer treatment

Aflac announced that it has raised more than $1.16 million for the Aflac Cancer Center through a matching grant campaign with Causes on Facebook, making it the largest sponsored campaign in the history of Causes. The effort also resulted in 851,215 new members joining the Aflac Cancer Center Cause, helping to generate awareness and financial support during Childhood Cancer Awareness Month.

8 Oct 2009

Study: Patients experience sleep apnea after opharyngeal cancer treatment

Nearly all patients who underwent surgery to treat oropharyngeal cancer experienced some degree of obstructive sleep apnea (OSA), according to new research presented at the 2009 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, in San Diego, CA.

7 Oct 2009

Researchers find increase in the number of procedures performed for dermatologic health care

Researchers from Boston University School of Medicine (BUSM) and the Laser and Skin Cancer Center of Indiana, (Carmel, Indiana), found that there has been a dramatic increase in the number of procedures performed and patient demand for dermatologic health care since 2000. The findings, which were recently reported in Dermatologic Surgery, parallels the growth in the age of individuals between the ages of 40 to 55, who make up the "Baby Boomer" generation.

6 Oct 2009

Scientists identify new interference method to target cancer cells

Professor Jo Milner and Dr Shafiq Ahmed, from the YCR P53 Research Unit in the Department of Biology, used a process called RNA interference to target the JNK2 gene in both cancer and healthy cells. The cancer cells died but the healthy cells were unaffected.

6 Oct 2009

$16 million federal stimulus funds for cancer research projects

Researchers at Fred Hutchinson Cancer Research Center, Group Health Research Institute and the University of Washington schools of Public Health and Pharmacy have been selected to lead four projects backed by approximately $16 million in federal stimulus funding for comparative-effectiveness research in cancer.

6 Oct 2009

Scientists uncover the role of first-responder molecule involved in repairing DNA strand breaks

Scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory and the Scripps Research Institute have uncovered the role played by the least-understood part of a first-responder molecule that rushes in to bind and repair breaks in DNA strands, a process that helps people avoid cancer.

5 Oct 2009

Few risks to babies born to parents who underwent cancer treatment in childhood: Study

Whether they can have children is one of the major concerns for adult survivors of childhood and adolescent cancer because fertility can be compromised by cancer treatment. For cancer survivors who can have children, two new studies led by researchers at Fred Hutchinson Cancer Research Center may help alleviate fears that their childhood disease will adversely impact their newborns.

3 Oct 2009

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Quest PharmaTech Inc. ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has acquired a pipeline of late-stage immunotherapy product candidates from Paladin Labs Inc. ("Paladin").

3 Oct 2009

New strategic research service for the oncology market launched by Health Strategies Group

Health Strategies Group, a leading provider of market intelligence to the pharmaceutical and biotechnology industries, has just launched Oncology Performance Edge, a new strategic research service that helps marketing and sales executives in the oncology field improve brand performance by understanding how best to invest their resources.

3 Oct 2009

66 percent of women unaware about accreditation of breast care centers: ACoS survey

According to new research from the American College of Surgeons (ACoS), two-thirds of women (66 percent) did not know about accreditation of breast care centers, what it means, and why it is important. However, after providing women who were surveyed with an overview of the meaning of accreditation, they overwhelmingly (92 percent) find it to be an important aspect in choosing a breast cancer treatment facility.

3 Oct 2009

61 institutions awarded grants for cancer research from American Cancer Society

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 new national research and training grants totaling $45,097,000 to 61 institutions nationwide in the second of two grants cycles for 2009. The grants go into effect beginning January 1, 2010.

3 Oct 2009

Clinical study results of prostate cancer patients treated with CyberKnife Radiosurgery released

Accuray Incorporated, a global leader in the field of radiosurgery, announced today publication of results from a study of early stage prostate cancer patients treated with CyberKnife Radiosurgery.

1 Oct 2009

Hospira acquires global rights to biogeneric filgrastim from PLIVA

Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today announced the acquisition of worldwide rights to a biogeneric version of filgrastim and an affiliated European manufacturing facility from PLIVA Hrvatska d.o.o. (Zagreb, Croatia) (ZSE: PLVA-R-A), a move that will help extend Hospira's reach and vertical integration in biogenerics. Financial terms of the agreement were not disclosed.

1 Oct 2009

St. Mary Medical Center offers Frameless Stereotactic Radiosurgery treatment to fight cancer

For patients diagnosed with a brain tumor, St. Mary Medical Center is among the first in the region to offer Frameless Stereotactic Radiosurgery (SRS) as a breakthrough treatment to fight cancer. Frameless Stereotactic Radiosurgery is a one-time application of a large-dose radiation precisely targeting a tumor.

1 Oct 2009

Bristol-Myers announces availability of ERBITUX for metastatic colorectal cancer treatment

Bristol-Myers Squibb Canada is pleased to announce that the Ontario government has made ERBITUX(TM) (cetuximab) available to patients suffering from metastatic colorectal cancer. This decision makes Ontario the second province, after British Columbia, to introduce funding for this important treatment option and represents encouraging news for those patients who rely on provincial drug coverage and stopped responding to standard treatments for metastatic colon cancer.

1 Oct 2009

SBIR grant from NIH to GenVec for metastatic cancer research

GenVec, Inc. announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the research of a new approach to treating metastatic cancer. Under this grant, valued at over $300,000, GenVec will investigate the hypothesis that the delivery of a specific gene will stimulate an antitumor response that could control cancer metastases.

30 Sep 2009

New center for gastrointestinal cancer research established

Georgetown University Medical Center today announced the creation of a center that may help advance a cure for one of the deadliest forms of cancer. The Otto J. Ruesch Center for the Cure of Gastrointestinal (GI) Cancers will fund gastrointestinal cancer research, drug discovery and patient advocacy efforts at the Georgetown Lombardi Comprehensive Cancer Center.

30 Sep 2009

San Francisco Medical Center acquires a BSD-500 Hyperthermia System

BSD Medical Corporation announced today that the University of California, San Francisco Medical Center (UCSF) has acquired a BSD-500 Hyperthermia System (BSD-500). UCSF is a world leader in hyperthermia and has the largest and most versatile hyperthermia program on the West Coast, and its world-renowned Radiation Oncology team has added the capabilities of the BSD-500 to its growing hyperthermia cancer treatment program.

29 Sep 2009

CEO Cancer Gold Standard accreditation for State Farm

State Farm has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

29 Sep 2009

NovoCure initiates newly-diagnosed GBM clinical trial

NovoCure, Ltd., a privately held medical device company focused on developing the Novo-TTF device, a non-invasive portable medical device for the treatment of cancer, announced the completion of a new funding round today. Key investors in this round included Pfizer Inc, Johnson & Johnson Development Corporation and Index Ventures.

29 Sep 2009

Cancer Treatment News and Research

Aflac raises $1.16 million through a grant campaign for pediatric cancer treatment

Study: Patients experience sleep apnea after opharyngeal cancer treatment

Researchers find increase in the number of procedures performed for dermatologic health care

Scientists identify new interference method to target cancer cells

$16 million federal stimulus funds for cancer research projects

Scientists uncover the role of first-responder molecule involved in repairing DNA strand breaks

Few risks to babies born to parents who underwent cancer treatment in childhood: Study

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

New strategic research service for the oncology market launched by Health Strategies Group

66 percent of women unaware about accreditation of breast care centers: ACoS survey

61 institutions awarded grants for cancer research from American Cancer Society

Clinical study results of prostate cancer patients treated with CyberKnife Radiosurgery released

Hospira acquires global rights to biogeneric filgrastim from PLIVA

St. Mary Medical Center offers Frameless Stereotactic Radiosurgery treatment to fight cancer

Bristol-Myers announces availability of ERBITUX for metastatic colorectal cancer treatment

SBIR grant from NIH to GenVec for metastatic cancer research

New center for gastrointestinal cancer research established

San Francisco Medical Center acquires a BSD-500 Hyperthermia System

CEO Cancer Gold Standard accreditation for State Farm

NovoCure initiates newly-diagnosed GBM clinical trial

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News